Using male peer networks to improve HIV prevention engagement
Official title: Harnessing Male Peer Networks to Enhance Engagement With HIV Prevention: A Large-scale Cluster Randomized Trial to Increase HIV Self-testing and PrEP Uptake Among Men in Eastern Zimbabwe
Run by University of Stellenbosch · NCT06370923 · Data updated 2026-11-12
This study is testing whether using male friends to share HIV self-testing kits can help men in Eastern Zimbabwe get better access to HIV prevention services like PrEP.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 3591 (estimated) |
| Sponsor | University of Stellenbosch Academic / other |
| Locations | 1 site (Mutare, Manicaland Province) |
| Status | Recruiting |
| Started | October 21, 2024 |
| Main results expected | May 31, 2028 |
| Study ends | May 31, 2028 |
| Registry record updated | May 4, 2025 |
| Trial ID | NCT06370923 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult men residing in the Manicaland province of Zimbabwe.
✕Probably not a fit
Patients who are not residents of the study site or who do not engage with male peer networks may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to enhance engagement with HIV testing and prevention services among men in Sub Saharan Africa, particularly in Eastern Zimbabwe. It employs an implementation science approach to distribute HIV self-testing kits through male social networks, supported by phone-based assistance and improved risk perception. The study utilizes a cluster-randomized trial design, recruiting participants from existing village boundaries to assess the impact of peer distribution on the uptake of Pre-Exposure Prophylaxis (PrEP). The intervention is designed to address barriers to HIV prevention and testing in the target population.
Why it matters
Potential benefit: If successful, this approach could significantly increase HIV prevention and testing among men, ultimately reducing new infections.
How similar studies have gone: Previous studies have shown promise in using peer networks for health interventions, suggesting this approach could be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Resident in study site
Where it's running
-
BRTI - Manicaland Centre for Public Health Research
Mutare, Manicaland Province, Zimbabwe Recruiting
Study contacts
- Principal investigator: Frank Tanser, PhD — University of Stellenbosch
- Study coordinator: Constance Nyamukapa, PhD
- Email: nyamukapaconnie@gmail.com
- Phone: +263 71 480 4050
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Camino HIV Prevention and Care Study
This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.
-
VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body
This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.
-
Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use
In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.
-
Metabolic Liver Disease in People Newly Diagnosed with HIV
This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.
-
Screen2Prevent: HIV screening for teens and young adults in emergency departments
The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.
-
Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART
This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.